Ketamine-based therapies have become one of the most widely discussed advancements in modern depression treatment. Yet for many patients, the terminology itself can create confusion. Questions like “Is SPRAVATO® the same as ketamine therapy?” or “Why are some treatments covered by insurance while others are not?” are extremely common.
These are important distinctions. While these treatments are related, they differ meaningfully in how they are administered, regulated, and accessed. Understanding those differences can help patients feel more confident when exploring advanced care options.
What Ketamine-Based Treatments Have in Common
Despite their variations, ketamine therapies share a central mechanism. Unlike traditional antidepressants (e.g.SSRIs), which primarily target 1% of neurotransmitters such as serotonin, dopamine, and norepinephrine, ketamine-based treatments act on the brain’s glutamate system.
Glutamate, which makes up 40% of the brain, plays a critical role in neural communication, brain connectivity, and synaptic plasticity. This distinction helps explain why ketamine therapies are often considered for individuals experiencing treatment-resistant depression or persistent symptoms that have not responded adequately to standard medications.This also explains why many patients experience reprieve from their depression after trying Ketamine therapy.
Intravenous (IV) Ketamine Therapy
IV ketamine therapy involves delivering ketamine directly into the bloodstream through a controlled infusion. This approach is widely offered in specialized ketamine clinics and has been used for years in medical settings, including anesthesia. When used for depression, however, IV ketamine is considered off-label, meaning it has not received specific FDA approval for this indication.
Many patients are drawn to IV ketamine because of reports of rapid symptom relief. However, treatment protocols, dosing strategies, and monitoring practices can vary between providers. Insurance coverage is also uncommon, which often makes this option a self-pay investment.
Intramuscular (IM) Ketamine Injections
Intramuscular (IM) ketamine follows a similar therapeutic concept but is administered via injection into muscle tissue rather than infusion, not unlike a shot. While the clinical effects may resemble IV therapy, the onset and intensity can feel different for some individuals.
Like IV ketamine, IM injections are typically used off-label for depression. As a result, insurance reimbursement remains limited, and treatment models may differ depending on the clinic.
SPRAVATO® Esketamine Nasal Spray
SPRAVATO® is a unique and distinct treatment within the ketamine landscape. Derived from ketamine’s esketamine molecule, SPRAVATO® is FDA-approved specifically for treatment-resistant depression and operates under a highly regulated Risk Evaluation and Mitigation Strategy (REMS) program.
Unlike IV or IM ketamine, SPRAVATO® must be administered in certified medical clinics under standardized protocols. Patients self-administer the nasal spray under supervision and remain in the clinic for observation afterward. This structure exists to ensure safety, consistency, and proper monitoring.
One of the most significant differences for patients is insurance accessibility. Because SPRAVATO® is FDA-approved for depression, it is often covered by insurance plans, making it a more financially feasible option for many individuals.
Differences in Treatment Experience
Although ketamine therapies influence similar brain systems, the patient experience can vary. IV and IM ketamine treatments often produce noticeable effects during administration, with intensity influenced by dosing strategies. SPRAVATO®, by contrast, follows a structured psychiatric treatment model designed around controlled dosing and observation.
Side effects like dissociation or altered perception are common across all ketamine-based therapies but may differ in intensity depending on the administration type.
Insurance Coverage Differences
Patients frequently wonder why chemically related treatments are treated so differently by insurance providers. The answer largely lies in regulatory approval. Insurance companies generally require FDA approval to provide consistent coverage, and SPRAVATO® meets that threshold while most IV and IM ketamine treatments do not.
This distinction is not necessarily a reflection of effectiveness, but rather of regulatory classification and standardization resulting in different financial accessibility.
Choosing the Right Approach
There is no universal “best” ketamine treatment. The appropriate option depends on factors such as treatment history, symptom severity, medical background, insurance considerations, and personal comfort.
What remains consistent across all pathways is the importance of clinical evaluation. A qualified provider can help determine whether ketamine-based therapy is appropriate and, if so, which format may align best with an individual’s needs.
Ketamine-based treatments represent an important expansion of modern depression care. For individuals who have not found relief through traditional medications alone, these therapies offer additional possibilities rooted in evolving neuroscience.
If you are in the Columbus, Ohio area and have questions about SPRAVATO® or other advanced depression treatment options, EverHope Wellness is here to help you explore your next steps with clarity, safety, and support.
Resources
National Institute of Mental Health. Depression — overview and treatment considerations. https://www.nimh.nih.gov/health/topics/depression
Daly, E. J., et al. (2018). Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. American Journal of Psychiatry, 175(2), 139–148.
https://pubmed.ncbi.nlm.nih.gov/29282469/
Mandal, S., Sinha, V. K., & Goyal, N. (2019). Efficacy of ketamine therapy in the treatment of depression. Indian journal of psychiatry. https://pmc.ncbi.nlm.nih.gov/articles/PMC6767816/
